Search Results
2022 PRO Consortium Workshop: Use and Interpretation of Meaningful Within-Person Change Thresholds
2022 PRO Consortium Workshop: Session 1: FDA Update
2021 PRO Consortium Workshop - FDA Update
2022 PRO Consortium Workshop: Welcome and Patient-Reported Outcome Consortium Update
2022 PRO Consortium Workshop: Session 3: Using Digital Health Technology to Measure What Matters
2021 PRO Consortium Workshop: Identifying COAs for Use in Rare Disease Treatment Trials
2022 Spring Technical Workshop: Session 1B: Capacity Accreditation and Market Constructs
Progress in Variant Interpretation for Cancer Susceptibility Genes: CanVar-UK Platform
Variant interpretation: from the clinic to the lab… and back again
Public Webinar: Patient-Focused Drug Development Draft Guidance 3
eCOA: Getting Better Together Initiative – Update from C-Path’s PRO Consortium and ePRO Consortium
Public Meeting: Using Methods from PFDD Guidance 1 and Guidance 2 Meeting #2
